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BUDGET IMPACT ANALYSIS OF SOMATULINE AUTOGEL IN THE MANAGEMENT
OF ACROMEGALY IN SPAIN
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OBJECTIVES: Acromegaly is a rare disease with an estimated incidence of 2.5 cases
per million (cpm) and a prevalence of 50-60 (cpm) per year according to Spanish
national data. Somatuline Autogel (Ipsen property) and Sandostatin LAR (Novartis
property) are associated with similar efficacy and together they represent more
than 90% of long-acting somatostatin analogs sales in Spain. Somatuline Autogel
has been approved of an injection extended dosing interval for 6 or 8 weeks with
the dose of 120mg. This study is aimed to estimate the potential budgetary conse-
quences of increasing the use of Somatuline Autogel in the treatment of acromeg-
aly in Spain.METHODS: A budget impact model was developed to compare annual
treatment costs of acromegaly patients with either Somatuline Autogel and San-
dostatin LAR, including drug acquisition costs and administration costs. Disease
prevalence and IMS sales data were used to estimate total number of patients using
both treatments, and the potential budget impact of increasing Somatuline Autogel
was calculated under different scenarios based on the proportion of patients using
different dose ranges. RESULTS: Overall treatment costs were 11,857€ and 12,165€
per patient/year for Somatuline Autogel and Sandostatin LAR respectively
(monthly treatment), as a result of the higher acquisition cost and administration
costs of the latter. Furthermore, assuming that 30% of patients with Somatuline
Autogel may benefit of the extended dose interval (every 6 or 8 weeks), mean cost
savings per patient may rise to 2,019€ (10,147€ vs. 12,165€). When applying these
patient-level cost savings with Somatuline Autogel to total treated patients, acro-
megaly treatment costs could be reduced by 0.3 M€ to 1.2 M€ by increasing the
proportion of patients treated with Somatuline Autogel from current 42% up to 50%
and 70% respectively in Spain. CONCLUSIONS: Using Somatuline Autogel in acro-
megaly patients is associated with favorable economic outcomes when compared
to other long-acting somatostatin analogs in Spain.
PSY11
BUDGET IMPACT MODEL OF HEMOPHILIA A TREATMENT IN TURKEY: A
PAYER’S PERSPECTIVE
Kayadibinli M, Ulus P, Durguner B
Pfizer Pharmaceuticals, Istanbul, Turkey
OBJECTIVES: According to World Federation of Hemophilia, more than 90% of cost
of hemophilia treatment is the cost of factor replacement. Currently, 13 different
Factor VIII products are available in Turkish market. These are classified as bio-
equivalent and these products are neither included in a willingness to pay thresh-
old nor in a pharmacoeconomic analysis before the reimbursement decision. The
aim of this study is determining the budget impact of possible cost minimization
strategies in reimbursement of Factor VIII products via investigating current reim-
bursement conditions and evaluation of possible ways for inserting cost minimi-
zation from the Payer’s perspective. METHODS: IMS data (September 2009-2010) is
evaluated for Factor VIII products in Turkish market. Current reimbursed prices are
evaluated for determination of particular patterns of reimbursement. Annual vol-
ume of Factor VIII consumption and annual cost of Factor VIII consumption are
linked and re-defined for cost minimization estimates in Microsoft 2003 Excel.
TreeAgePro2011 is used for calculations and decision tree structuring. RESULTS:
Annual consumption of Factor VIII products constitutes 128,319,000 IU and an
annual cost of 129,806,872.88 TL. The Payer can imply cost minimization strategies
(change reimbursement strategies and/or eliminating waste) resulting in gradual
reduction from total expenditure as 2.6% (3,390,029.43 TL/year), 2.8% (3,610,300.16
TL/year), 5.7% (7,357,325.35 TL/year), 18.9% (24,595,818.19 TL/year) and 20.8%
(27,059,457.55 TL/year). CONCLUSIONS: Payer may apply following steps for cost
minimization, therefore obtaining a positive budget impact for Factor VIII spending
in Turkey; Step1: Evaluation of all Factor VIII products according to the reimbursed
prices; Step2: Classification of reimbursement pattern for each product; Step3:
Standardization of reimbursement patterns for all products; Step4: Promotion of
differentiation for availability of forms; Step5: Monitoring annual budget impact
effect of all previous steps.
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COMPARISON OF THE MOST COMMON REASONS FOR INPATIENT ADMISSIONS
AMONG FIBROMYALGIA PATIENTS ON DULOXETINE VERSUS PREGABALIN
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OBJECTIVES: To examine the most common reasons for inpatient admissions
among fibromyalgia patients who initiated duloxetine or pregabalin. METHODS:
Using a large US national commercial healthcare claims database, fibromyalgia
patients aged 18-64 who initiated duloxetine or pregabalin in 2006 were identified.
All patients included had 12-month continuous enrollment before and after the
initiation, and at least 31 total duloxetine or pregabalin supply days over the 12-
month post-index period. Propensity scoring was applied to construct duloxetine
and pregabalin cohorts with similar demographics, pre-index clinical and eco-
nomic characteristics, and pre-index treatment patterns. Reasons for inpatient
admissions between the cohorts were examined. Logistic regressions were used to
assess the contribution of duloxetine versus pregabalin initiation to the top rea-
sons for inpatient admissions controlling for cross-cohort differences. RESULTS:
Per our study design, duloxetine (n3,711) and pregabalin (n4,111) patients had
similar demographics with a mean age of 51 years and 83% females. Both cohorts
had similar co-morbidities, with cardiovascular disease being the most common.
Duloxetine and pregabalin patients, by the study design, also had similar total
health care costs over the 12-month pre-index period ($18,970 vs. $19,019, p0.994)
with 22% contributed by inpatient care. Eight of the top 10 reasons for inpatient
admissions over the 12-months post-index period were the same for both groups
with intervertebral disc disorder, osteoarthritis of lower leg, and chest pain being
the top 3 leading reasons. Controlling for cross-cohort differences, duloxetine pa-
tients were at a significantly lower risk for hospitalizations due to intervertebral
disc disorder or major depression disorder (MDD) (odds ratios0.44, 0.81, respec-
tively; both p0.0001).CONCLUSIONS:Among similar commercially-insured fibro-
myalgia patients who initiated duloxetine or pregabalin, the leading reasons for
inpatient admissions were somewhat different between groups. Compared to pre-
gabalin initiators, duloxetine initiators tended to be less likely to have inpatient
admissions due to intervertebral disc disorder or MDD.
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OBJECTIVES: To examine the most common reasons for primary or specialty care
visits among fibromyalgia patients initiated duloxetine or pregabalin. METHODS:
Using a large US commercially-insured administrative claims database, we exam-
ined fibromyalgia patients aged 18-64 who initiated duloxetine or pregabalin in
2006. All patients were required to have 12 months of continuous enrollment prior
to and after the initiation. Applying propensity scoring, we constructed the dulox-
etine and pregabalin cohorts to have similar demographics, comorbid medical
conditions, prior healthcare utilization and costs, and prior medication use. Using
the first diagnosis recorded in all outpatient claims, we examined the reasons for
primary vs. specialty care over the 12-month post-index period. Controlling for
cross-cohort differences, we assess the impact of duloxetine vs. pregabalin initia-
tion on the top reasons for primary care or specialty care visits via logistic
regressions. RESULTS: The study sample included 3,711 duloxetine and 4,111 pre-
gabalin patients with a mean age of 51 years and around $19,000 prior total health-
care costs. Duloxetine and pregabalin patients shared 8 (9) out of the 10 top reasons
for primary (specialty) care visits, with most of the prevalence rates/10,000 being
higher (lower) among the duxeteine patients. Controlling for cross-cohort differ-
ences, duloxetine patients were more likely to have a primary care visit due to
disorder of soft tissue, essential hypertension, or other general symptoms (odds
ratios1.12, 1.16, 1.14, respectively), but less likely to go to specialty care due to
disorder of soft tissue, nonspecific backache/other back/neck pain, or interverte-
bral disc disorder (odds ratios0.83, 0.69, 0.63, respectively) (all p0.05).
CONCLUSIONS: Among commercially-insured fibromyalgia patients who initiated
duloxetine or pregabalin, the most common reason for primary or specialty care
was somewhat different. Duloxetine initiators tended to be less likely to use spe-
cialty care, and more likely to use primary care for disorder of soft tissue.
PSY14
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OBJECTIVES: To examine the most common reasons for physician office visits,
outpatient hospital visits, and emergency room (ER) visits among fibromyalgia
patients who initiated duloxetine or pregabalin.METHODS: Commercially-insured
fibromyalgia patients aged 18-64 who initiated duloxetine or pregabalin in 2006
were examined. All patients selected had continuous enrollment during the 12
months before and after the initiation. Each patient was classified into the dulox-
tetine or pregabalin cohort based on the index medication, and both cohorts were
constructed via propensity scoring to have similar demographics, comoribidities,
prior healthcare costs, and prior pain-related medication use. Reasons for physi-
cian office, outpatient hospital, and ER visits over the 12 months post-index period
were examined for both cohorts. The impact of duloxetine vs. pregabalin initiation
on the top reasons leading to physician office, outpatient hospital, or ER visits was
examined via logistic regressions controlling for the cross-cohort differences.
RESULTS: A total of 3711 duloxetine and 4111 pregabalin patients were included
with a mean age of 51 years and 83% being female. Duloxetine and pregabalin
patients had similar total healthcare costs ($18,970 vs. $19,019, p0.994) over the 12
months pre-index period, with 52-53% contributed by the outpatient care. Both
groups shared 9 out of the top 10 reasons for physician office visits, 7 of the 10 most
common reasons for outpatient hospital visits, and 8 of the top 10 reasons for ER
visits. Controlling for cross-cohort differences, duloxetine patients were less likely
to have a physician office visit due to nonspecific backache/other back/neck pain
but more likely to go to the ER due to other general symptoms (odds ratios0.91,
1.43, respectively, both p0.001). CONCLUSIONS: Among commercially-insured
fibromyalgia patients who had similar demographic and clinical characteristics
and initiated duloxetine or pregabalin in 2006, the leading reasons were somewhat
different for physician office visits, outpatient hospital or ER visits.
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Erythropoiesis’ Stimulating Factors (ESAs) are among the top ten therapeutic
groups with the highest pharmaceutical expenditure in Greece. OBJECTIVES: To
explore the penetration of ESAs in the Greek pharmaceutical market and differ-
ences in pricing levels between originals and biosimilars. METHODS: Data derived
from the IKA-ETAM Social Security Fund, covering almost 50% of insured popula-
tion. Consumption of ESAs (epoetin alfa, darbepoetin alfa, epoetin beta, methoxy
polyethylene glycol epoetin beta, epoetin zeta) was collected from the Central &
Peripheral Pharmacy, dispensing high value medicines for serious diseases on out-
patient basis covering almost 70% geographical area of Greece. Consumption of
epoetins was recorded from 2008 to 2010, classified per strength (IU/mcg), sepa-
rated in originals and biosimilars. The average price per 1000IU of each category
was also estimated for the respective years based on NHS hospital prices.RESULTS:
ESAs consumption in 2008 and 2009 was approximately the same (26 & 27% respec-
tively) while decreasing by 4% reaching 23% in 2010. A 13,8% decrease was also
observed in IKA-ETAM total pharmaceutical expenditure in 2010. ESAs expenditure
in 2008, was €41,4 million corresponding to 99% market share (MSH) of originals
epoetins, leaving only 1% MSH in biosimilar epoetin zeta launched in that year. In
2009 ESAs expenditure reached €43 million, with 94% and 6% MSH for original and
biosimilar ESAs respectively. In 2010 ESAs expenditure was almost halved (€22mil-
lion), due to price cuts and stricter control of prescriptions. Specifically, the MSH of
originals reached 81% and biosimilars 19% respectively. In the reported years prices
of biosimilars were slightly different from that of originals, however as of 2011
higher price differences are observed, favoring the use of biosimilars.
CONCLUSIONS: Biosimilars penetration in Greece is similar with EU, 6% and 6,64%
in 2009 respectively, presenting an increasing rate in 2010. Under the economic
recession Greece is experiencing, biosimilars seem to be a cost saving option.
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COST AND QUALITY OF LIFE BENEFITS OF FASTER BLEED RESOLUTION WITH
AN RFVIIA ANALOGUE: A MATHEMATICAL SIMULATION STUDY FOR THE
GERMAN POPULATION
Pokras SM1, Petrilla AA1, Weatherall J2, Lee WC1
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OBJECTIVES: On-demand treatment for haemophilia patients with inhibitors is
burdensome to patients and practitioners. Newer bypassing agents with shortened
bleed resolution time resulting in fewer infusions, may impact costs and patient
quality of life (QoL). The study objective was to model the lifetime costs and health-
related QoL outcomes associated with bypassing agents, recombinant activated
Factor VIIa and plasma-derived activated prothrombin complex concentrate (rF-
VIIa, pd-aPCC) in Germany, and investigate the impact of faster bleeding resolution
of a new rFVIIa analogue. METHODS: Assuming a German payer perspective, this
literature-based model tracks a hypothetical cohort of severe haemophilia patients
with inhibitors over their lifetime. A semi-Markov model was used to simulate
patient movement through health states at 3-month intervals. Modeled outcomes
include lifetime direct treatment costs, cost per bleeding episode, life-years, and
quality-adjusted life years (QALYs) across a continuum of home and inpatient care.
One-way sensitivity analyses were performed on all model variables and two-way
sensitivity analyses on key variables. RESULTS:Using base-case assumptions from
the literature, rFVIIa was associated with measurable lifetime cost savings com-
pared with pd-aPCC (€ 2,962,833 vs. € 4,664,971, respectively) and reduced total cost
per bleed compared with pd-aPCC (€ 17,614 vs. € 19,435, respectively). Reducing the
number of rFVIIa infusions per bleed from 2.3 to 1.5 resulted in incremental cost
savings of € 248,033, while 20% utility improvement in rFVIIa conferred a 3.14
additional QALY gain. Sensitivity analyses confirmed the robustness of base case
findings.CONCLUSIONS:This exploratory model is a valuable tool for physicians to
assess the impact of current treatment patterns over a patient’s lifetime and to
potentially identify optimal practice patterns. Availability of bypassing agents with
improved efficacy profiles could result in significant improvement of patient care.
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RETROSPECTIVE CHART REVIEW STUDY OF THE COST OF CARE OF SYSTEMTIC
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Maurel F7, Roset M8, Perna A9, Schmitt C10, Ager M9, Boucot I11, Gonzalez McQuire S10,
Birch H10
1University of Padova, Padova, Padova, Italy, 2Université Paris VI Pierre et Marie Curie, Paris ,
France, 3Heinrich-Heine-University, Düsseldorf, Germany, 4Hospital Clínic, Barcelona, Spain,
5The Rayne Institute, London, UK, 6Centre d’épidémiologie clinique, Vandoeuvre-les-Nancy,
France, 7IMS Health, Paris, France, 8IMS Health, Barcelona, Spain, 9GlaxoSmithKline, Brentford,
UK, 10GlaxoSmithKline, Uxbridge, UK, 11GlaxoSmithKline, Marly-le-Roi, France
OBJECTIVES: Evaluate rate of flares in adult SLE patients with active antinuclear
autoantibody positive SLE disease and estimate the incremental direct costs of
flare management. METHODS: A multi-centre retrospective chart review study
extracting patient characteristics, disease activity and severity, and medical re-
source utilization in 5 European countries (France, Germany, UK, Italy and Spain).
Patients were stratified by disease severity at inclusion visit (50% severe) and fol-
lowed-up for 2 years. Severe disease defined as having at least one major domain
actively involved (renal, neurological, cardiovascular or respiratory) and requiring
7.5 mg/day of corticosteroids and/or immunosuppressants. A modification of
SELENA-SLEDAI Flare Index collected retrospectively was used for identifying mild/
moderate and severe flares. Unadjusted mean costs associated with management
of flares were assessed. Health care perspective and country specific data was used
for resources and costs analysis. RESULTS: The total sample included 427 SLE
patients (212 severe, 215 non-severe), mean age: 43.4 years, female: 90.5%. Total
mean number of flares over the study period was 2.29 compared to 1.83 (p0.001)
for severe and non-severe patients respectively. Mean number of mild/moderate
flares was 0.87 compared to 1.32 (p0.001), while mean number of severe flares was
1.42 compared to 0.52 (p0.001) for severe and non-severe patients, respectively.
The mean two year costs for patients experiencing at least one flare over study
period was €9607 compared to €3910 (p0.001) without flares. Exploratory flare
analysis showed a mean 2 year increase in costs of €4525 (p0.01) per severe flare
(no statistical significance for mild/moderate flares). CONCLUSIONS: Severe pa-
tients experience both a higher number of flares and more severe flares compared
to non-severe patients. Patients experiencing at least one flare over the study pe-
riod are 2.5 times more costly than patients without flares; the presence of severe
flares in SLE patients has a significant impact on the healthcare system.
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RESOURCE CONSUMPTION EVALUATION FOR KETOPROPHENE, KETOROLAC,
PARECOXIB AND TENOXICAM AT ORTHOPEDIC SURGERY POST-OPERATION IN
BRAZILIAN PATIENTS FROM PRIVATE PAYERS PERSPECTIVE
Fujii RK1, Mould JF2, Lanzara G3
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OBJECTIVES:The rational use of resources is essential for granting sustainability at
any healthcare system. This study aims to evaluate the best anti-inflamatory med-
ication regarding costs consumption from private payer’s perspective. METHODS:
400 medical charts from 3 private hospitals in Curitiba city were accessed retro-
spectively from November to April (2010) and selected based on the use of intrave-
nous ketoprophene (200mg/day), ketorolac (60mg/day), parecoxib (40mg/day) or
tenoxicam (40mg/day) at the immediate post-operative adult patients from ortho-
pedic surgeries period and based on the existence of hospital’s billing information.
One hundred twenty-one cases were recruited. Resource use considered were ant-
acid, antiemetic and analgesic drugs, infusion equipment, medication costs (fac-
tory list prices) and labor costs were estimated from the amount of minutes per day
to administering the medications. The minimum monthly wage for a nurse accord-
ing to the Brazilian nurses union was considered (593.75 USD). Costs are expressed
in 2010 USD. RESULTS: Parecoxib presented the least daily resource consuming
profile with an average of 33.52 USD compared to 68.27; 67.16 and 75.05 USD for
ketoprophene, ketorolac and tenoxicam. Daily average expenditure on the con-
sumption of antacid analgesic and antiemetic medications was 6.00, 10.19, 12.43
and 8.50 USD for parecoxib, ketoprophene, ketorolac and tenoxicam (PC/KP/KL/TM)
respectively. Total time expenditure per day and costs were 12.5 min (4.96 USD),
26.75 min (10.59 USD), 27.43min (10.85 USD) and 25.20 min (9.97 USD) for PC/KP/
KL/TM respectively. Daily savings by using parecoxib were found in 2.53, 13.04 and
7.16 USD against KP/KL/TM, respectively. CONCLUSIONS: Parecoxib was found to
be the less costly alternative to the hospital by rationing the number of adminis-
trations per day, the use of antacid, analgesic and antiemetic medications and the
total labor time costs for administering the medications.
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ECONOMIC COSTS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA
AMONG PATIENTS WITH NON-HODGKIN’S LYMPHOMA IN EUROPEAN
CLINICAL PRACTICE
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OBJECTIVES: Cost of chemotherapy-induced febrile neutropenia (FN) in the United
States has been reported to be substantial. Little is known about the cost of FN in
other countries or about costs of follow-on care and subsequent FN events.
METHODS: Data were obtained from an observational study of supportive care in
patients with non-Hodgkin’s lymphoma (NHL) receiving CHOP-14 or CHOP-21 che-
motherapy (rituximab) predominantly across Europe. FN was defined as single
oral temperature of38.3°C or temperature of38.0°C for1 hour, and neutrophil
count of 0.5x109/L or 1.0x109/L and predicted to fall below 0.5x109/L. Patients
developing FN in a given cycle (“FN patients”), starting with the first cycle, were
matched (1:1, without replacement) on age, tumor stage, chemotherapy, and other
factors to those not developing FN in that cycle (“comparison patients”), irrespec-
tive of FN experience in subsequent cycles. FN-related healthcare utilization and
costs (estimated from UK National Health Service perspective [2010]) were tallied
for patients from the match cycle through the last chemotherapy cycle
(“follow-up”). RESULTS: Eighteen percent of patients (331/1829) in the observa-
tional study experienced a total of 479 FN events, the majority (77%) of which
required inpatient care. A total of 295 FN patients were matched to comparison
patients for these analyses; baseline characteristics were similar between groups.
During follow-up, FN patients averaged 1.44 (95%CI 1.34-1.56) FN events and com-
parison patients averaged 0.15 (0.10-0.21) FN events, and corresponding mean
number of FN-related hospital days was 6.21 (5.28-7.17) and 0.63 (0.30-1.02). Mean
total cost was £5744 (£4893-£6664) higher for FN patients than comparison patients,
with 71% of the difference attributable to care in the index cycle (£4051 [£3633-
£4485]) and 29% attributable to care in post-index cycles (£1693 [£917-£2447]).
CONCLUSIONS: Cost of chemotherapy-induced FN among NHL patients in Euro-
pean clinical practice is substantial, with a sizable percentage attributable to fol-
low-on care and subsequent FN events.
PSY20
THE ANNUAL DIRECT MEDICAL COST OF SYSTEMIC LUPUS ERYTHEMATOSUS
(SLE) PATIENTS AND COSTS DRIVERS (LUCIE STUDY): FRENCH RESULTS
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